| 2024-11-20 | +0.28 % |
- Cigna (CI) stock rose by 0.28% likely due to the nomination of Dr. Mehmet Oz, who has significant investments in health insurance, including Cigna, as head of the Centers for Medicare & Medicaid Services, raising prospects of favorable policies that could benefit healthcare stocks.
- Cigna (CI) stock rose 0.28% last night, likely influenced by investor confidence and positive market trends, although the article primarily focuses on Public Service Enterprise Group (PEG) rather than Cigna.
- Cigna (CI) stock rose by 0.28% following the political appointment of Dr. Mehmet Oz, who, as the new overseer of the Centers for Medicare and Medicaid Services, supports policies that could expand the Medicare Advantage system, benefiting firms like Cigna.
|
| 2024-11-18 | +0.29 % |
|
| 2024-11-14 | -2.46 % |
|
| 2024-11-12 | -0.93 % |
|
| 2024-11-11 | +7.28 % |
|
| 2024-11-08 | +0.09 % |
|
| 2024-11-07 | +1.35 % |
|
| 2024-11-05 | +1.94 % |
|
| 2024-11-04 | -1.32 % |
|
| 2024-11-01 | +0.53 % |
|
| 2024-10-31 | +0.61 % |
|
| 2024-10-30 | +1.51 % |
|
| 2024-10-29 | -2.12 % |
|
| 2024-10-28 | -0.61 % |
|
| 2024-10-25 | -0.44 % |
|
| 2024-10-24 | +0.21 % |
|
| 2024-10-23 | +0.03 % |
|
| 2024-10-22 | -0.87 % |
- Cigna (CI) stock decreased by 0.87%, likely due to market fluctuations and investor sentiment influenced by recent financial reports and analyst ratings for related stocks in the sector.
- The Cigna (CI) stock fell by 0.87% due to broader market movements and investor reactions influenced by recent developments in the healthcare sector, particularly concerning competitors like Humana and market volatility surrounding related companies.
- Cigna (CI) stock fell by 0.87% after OLD National Bancorp IN disclosed a 19.9% reduction in its stake in the company, indicating a shift in investor confidence.
- Cigna (CI) stock declined by 0.87%, potentially due to a broader market trend following recent analyst downgrades and mixed earnings sentiments in the financial sector, as well as general market volatility impacting healthcare stocks.
- Cigna (CI) stock dipped by 0.87% following recent institutional investor activities, including capital increases, a sale by a company director, and mixed research analyst ratings, despite reporting strong quarterly earnings. The decline may be attributed to the stock's performance relative to investor expectations and insider selling, potentially signaling a lack of confidence among some stakeholders.
|
| 2024-10-21 | -4.69 % |
|
| 2024-10-18 | -4.85 % |
|
| 2024-10-17 | -1.52 % |
|
| 2024-10-16 | +2.79 % |
|
| 2024-10-15 | -0.74 % |
|
| 2024-10-14 | +0.33 % |
|
| 2024-10-11 | -0.06 % |
- The article discusses recent movements in institutional investments and analysts' ratings regarding Warner Bros. Discovery (WBD), while noting that Cigna (CI) stock was down by 0.06%. The decline in Cigna's stock price may not be directly addressed in the article but can be attributed to broader market trends or specific investor sentiment, as the article focuses primarily on WBD.
- The article discusses a recent decline of -0.06% in Cigna (CI) stock, attributed to changes in institutional investors' positions, including Park Avenue Securities LLC selling shares, which may reflect concerns or adjustments in market sentiment towards the company's stock.
- Cigna's stock (CI) declined by 0.06%, primarily due to ongoing challenges faced by retail pharmacies, including the impact of pharmacy benefit managers (PBMs) on reimbursement rates, which have contributed to numerous store closures and the growing issue of pharmacy deserts.
- Cigna (CI) stock declined by 0.06% as Perpetual Ltd significantly reduced its stake in the company by 85.8%, selling a large number of shares.
- Cigna (NYSE: CI) stock declined by 0.06% as Brendel Financial Advisors LLC significantly reduced its stake by 84% in the third quarter, indicating a potential decrease in investor confidence.
|
| 2024-10-10 | +1.09 % |
|
| 2024-10-09 | +0.81 % |
|
| 2024-10-07 | -0.42 % |
|
| 2024-10-04 | +0.33 % |
|
| 2024-10-03 | -0.04 % |
|
| 2024-10-02 | -2.12 % |
|
| 2024-10-01 | +0.48 % |
|
| 2024-09-30 | -0.36 % |
|
| 2024-09-27 | +0.79 % |
|
| 2024-09-26 | -1.11 % |
|
| 2024-09-25 | -1.22 % |
|
| 2024-09-24 | -0.5 % |
|
| 2024-09-23 | -0.34 % |
|
| 2024-09-20 | -0.31 % |
|
| 2024-09-19 | +0.53 % |
|
| 2024-09-18 | -0.24 % |
|
| 2024-09-17 | -2.89 % |
|
| 2024-09-13 | +0.7 % |
|
| 2024-09-11 | -0.09 % |
|
| 2024-09-10 | +0.14 % |
- Cigna (CI) stock has risen by 0.14% and has increased 25.6% over the past year, outperforming the industry and the S&P 500, driven by positive growth prospects in the medical sector.
- The Cigna Group (NYSE:CI) stock rose by 0.14% last night, supported by increased institutional investment, positive earnings results exceeding analyst expectations, and favorable broker ratings.
Cigna's stock went up due to various large investors, such as Private Advisor Group LLC and Vanguard Group Inc., boosting their stakes in the company, suggesting strong institutional confidence. Additionally, the company reported better-than-expected quarterly earnings and revenue growth, which likely contributed to an increase in stock price.
|
| 2024-09-03 | +1.01 % |
|
| 2024-08-30 | +0.21 % |
|
| 2024-08-15 | +0.54 % |
|
| 2024-08-14 | +0.66 % |
|
| 2024-08-13 | +1.41 % |
|
| 2024-08-01 | -4.61 % |
|
| 2024-07-25 | -0.31 % |
|
| 2024-07-24 | +1.8 % |
|
| 2024-07-23 | +0.11 % |
|
| 2024-07-22 | -0.01 % |
|
| 2024-07-19 | -1.37 % |
|
| 2024-07-18 | -1.23 % |
|
| 2024-07-17 | +1.49 % |
|
| 2024-07-15 | -1.01 % |
|
| 2024-07-10 | +0.47 % |
|
| 2024-07-09 | +1.42 % |
|
| 2024-07-03 | -0.15 % |
|
| 2024-07-02 | -0.11 % |
|
| 2024-06-27 | -1.02 % |
|
| 2024-06-18 | +0.27 % |
|
| 2024-06-13 | -0.57 % |
|
| 2024-06-12 | -0.77 % |
|
| 2024-06-11 | -0.21 % |
|
| 2024-06-06 | +1.12 % |
|
| 2024-06-05 | -0.85 % |
|
| 2024-05-31 | +4.11 % |
|
| 2024-05-29 | -0.09 % |
|
| 2024-05-28 | +0.18 % |
|
| 2024-05-23 | +0.4 % |
|
| 2024-05-22 | +0.03 % |
|
| 2024-05-21 | +0.9 % |
- The article discusses Alvotech's recent financial results and corporate highlights, including FDA approvals for biosimilar drugs, commercial partnership agreements, and positive clinical trial results. Cigna's stock went up as Alvotech announced a strategic partnership agreement with Quallent Pharmaceuticals, a subsidiary of Cigna group, for the distribution of Alvotech's biosimilar to Humira under Quallent's private label.
- The article provides details on Alvotech's recent developments, financial results, partnerships, and product launches, showing a positive outlook with raised revenue guidance; the rise in Cigna's (CI) stock could be attributed to Alvotech's strategic partnerships and progress in the commercialization of biosimilar medicines like Humira®, Stelara®, Prolia®, and Xgeva®.
- The article discusses Alvotech's recent financial results and corporate highlights, including FDA approvals and commercialization agreements. Cigna (CI) stock went up last night due to an announced U.S. strategic partnership agreement between Alvotech and Quallent Pharmaceuticals, a subsidiary of Cigna group, for the distribution of Alvotech's biosimilar to Humira under Quallent's private label, making it the first high-concentration, citrate-free biosimilar to Humira granted interchangeable status by the FDA.
|
